Maike Vom Hove
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Maike Vom Hove has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
C. Henn
Universitätsklinik und Poliklinik für Kinder und Jugendliche Leipzig, Arbeitsgruppe päd. Pulmologie
1 shared publicationConstance Henn
Pediatricians Office Dr. Henn, Pediatric Pulmonology, 04177 Leipzig, Germany
1 shared publicationEva Robel-Tillig
Pediatric Pneumology and Allergology, Hospital for Children and Adolescents, University of Leipzig, Leipzig, Germany
1 shared publicationF. Prenzel
Universitätsklinik und Poliklinik für Kinder und Jugendliche Leipzig, Arbeitsgruppe päd. Pulmologie
1 shared publicationFreerk Prenzel
Pediatric Pneumology and Allergology, Hospital for Children and Adolescents, University of Leipzig, Leipzig, Germany
1 shared publicationHolm H. Uhlig
Pediatric Pneumology and Allergology, Hospital for Children and Adolescents, University of Leipzig, Leipzig, Germany
1 shared publication
Latest Publications
- Open Access
- 8 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (10) , 4487
Identification and Characterization of a Rare Exon 22 Duplication in CFTR in Two Families
Accurate genetic diagnosis is essential for appropriate treatment in cystic fibrosis (CF). Large copy number variants like duplications in the CFTR gene are rare and often classified as variants of uncertain significance (VUSs) due to unknown characteristics of the inserted material, complicating diagnosis and treatment decisions. We identified a previously uncharacterized exon 22 duplication (CFTRdup22) in the CFTR gene in two anamnestically unrelated people with CF, both exhibiting a mild phenotype. Initial classification as a VUS was based on standard genetic testing. We employed a custom next-generation sequencing (NGS) panel to determine the exact breakpoints of the duplication and conducted mRNA sequencing to confirm its effect on splicing. DNA and RNA analyses allowed for precise breakpoint determination, confirming that the duplication was in tandem and the reading frame remained intact. This, as well as a residual CFTRdup22 function of ~30% as measured via intestinal current measurement, is consistent with a clinically milder CF phenotype. Collectively, the precise characterization of the variants’ breakpoints, localization and orientation enabled us to reclassify the variant as likely pathogenic. This study highlights the importance of advanced genetic techniques, such as NGS and breakpoint analysis, in accurately identifying CF-causing variants. It underscores the importance of a comprehensive approach and persistence when suspecting a specific genetic condition. This can aid in reclassifying VUSs, providing a definitive diagnosis for the affected family and enabling appropriate therapeutic interventions, including the use of CFTR modulators.
- 8 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (10) , 4487
Open AccessIdentification and Characterization of a Rare Exon 22 Duplication in CFTR in Two Families
Accurate genetic diagnosis is essential for appropriate treatment in cystic fibrosis (CF). Large copy number variants like duplications in the CFTR gene are rare and often classified as variants of uncertain significance (VUSs) due to unknown characteristics of the inserted material, complicating diagnosis and treatment decisions. We identified a previously uncharacterized exon 22 duplication (CFTRdup22) in the CFTR gene in two anamnestically unrelated people with CF, both exhibiting a mild phenotype. Initial classification as a VUS was based on standard genetic testing. We employed a custom next-generation sequencing (NGS) panel to determine the exact breakpoints of the duplication and conducted mRNA sequencing to confirm its effect on splicing. DNA and RNA analyses allowed for precise breakpoint determination, confirming that the duplication was in tandem and the reading frame remained intact. This, as well as a residual CFTRdup22 function of ~30% as measured via intestinal current measurement, is consistent with a clinically milder CF phenotype. Collectively, the precise characterization of the variants’ breakpoints, localization and orientation enabled us to reclassify the variant as likely pathogenic. This study highlights the importance of advanced genetic techniques, such as NGS and breakpoint analysis, in accurately identifying CF-causing variants. It underscores the importance of a comprehensive approach and persistence when suspecting a specific genetic condition. This can aid in reclassifying VUSs, providing a definitive diagnosis for the affected family and enabling appropriate therapeutic interventions, including the use of CFTR modulators.
- 1 January 2014
- Published by Elsevier in The Journal of Pediatrics
- Vol. 164 (1) , 40-45.e4
Pulmonary Outcome in Former Preterm, Very Low Birth Weight Children with Bronchopulmonary Dysplasia: A Case-Control Follow-Up at School Age
- 1 January 2014
- Published by Elsevier in The Journal of Pediatrics
- Vol. 164 (1) , 40-45.e4
Pulmonary Outcome in Former Preterm, Very Low Birth Weight Children with Bronchopulmonary Dysplasia: A Case-Control Follow-Up at School Age
- 1 January 2011
- Published by Georg Thieme Verlag KG in Kinder- und Jugendmedizin
- Vol. 11 (01) , 38-42
Pulmonale Langzeitfolgen der bronchopulmonalen Dysplasie
Zusammenfassung: Die bronchopulmonale Dysplasie (BPD) stellt eine der bedeutendsten Komplikationen der Frühgeburtlichkeit dar. Sie ist nach wie vor die häufigste chronische Lungenerkrankung im Kleinkindesalter. Frühgeborene mit BPD können bis ins Erwachsenenalter hinein unter pulmonalen Einschränkungen wie Atemwegsobstruktion und Überblähung sowie persistierenden respiratorischen Beschwerden leiden. Frühgeborene aus der Surfactant-Ära scheinen gleichermaßen von den Langzeitfolgen der BPD betroffen zu sein. Unklar ist, ob ein mögliches besseres Langzeitoutcome durch das Überleben von immer unreiferen Frühgeborenen verdeckt wird. Beim Management von Patienten mit chronischer Lungenerkrankung nach BPD sollte auf eine Abgrenzung zum Asthma bronchiale geachtet werden. Bisher konnte kein positiver Effekt einer Therapie mit inhalativen Steroiden beobachtet werden. Die Anwendung von inhalativen Bronchodilatatoren wird bisher nur bei Anzeichen einer reversiblen Atemwegsobstruktion oder Exazerbationen empfohlen.
- 1 January 2011
- Published by Georg Thieme Verlag KG in Kinder- und Jugendmedizin
- Vol. 11 (01) , 38-42
Pulmonale Langzeitfolgen der bronchopulmonalen Dysplasie
Zusammenfassung: Die bronchopulmonale Dysplasie (BPD) stellt eine der bedeutendsten Komplikationen der Frühgeburtlichkeit dar. Sie ist nach wie vor die häufigste chronische Lungenerkrankung im Kleinkindesalter. Frühgeborene mit BPD können bis ins Erwachsenenalter hinein unter pulmonalen Einschränkungen wie Atemwegsobstruktion und Überblähung sowie persistierenden respiratorischen Beschwerden leiden. Frühgeborene aus der Surfactant-Ära scheinen gleichermaßen von den Langzeitfolgen der BPD betroffen zu sein. Unklar ist, ob ein mögliches besseres Langzeitoutcome durch das Überleben von immer unreiferen Frühgeborenen verdeckt wird. Beim Management von Patienten mit chronischer Lungenerkrankung nach BPD sollte auf eine Abgrenzung zum Asthma bronchiale geachtet werden. Bisher konnte kein positiver Effekt einer Therapie mit inhalativen Steroiden beobachtet werden. Die Anwendung von inhalativen Bronchodilatatoren wird bisher nur bei Anzeichen einer reversiblen Atemwegsobstruktion oder Exazerbationen empfohlen.